Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501364 | 0.85 | ELANE (0.33) | PARP1ELANE | |
| SCHEMBL6488965 | 0.80 | ERN1 (0.38) | CYP3A4KDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL6492079 | 0.76 | PDGFRB (0.35) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6490421 | 0.74 | PDE3B (0.40) | CYP3A4KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6499100 | 0.71 | PFKFB3 (0.37) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11417483 | 0.70 | MEN1 (0.46) | PARP1ELANEKDM4EMEN1ALDH1A1 | |
| SCHEMBL6502506 | 0.69 | ERN1 (0.38) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6489727 | 0.67 | TYK2 (0.62) | TYK2JAK2CYP3A4JAK1MEN1 | |
| SCHEMBL9276050 | 0.62 | KMT2A (0.43) | CYP3A4KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3456737 | 0.62 | PSMB8 (0.41) | PARP1ELANECYP3A4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908932-B2 | Cancer therapy | ICONIX PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | ENTELOS HOLDING CORP. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035618-A2 | MODULATORS OF PHOSPHOINOSITIDE 3-KINASE | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | PIK3R1, PIK3R3, PIK3R4 | PARP1 2261/4885ELANE 3614/4885TYK2 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.